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Telomerase activity in pancreatic endocrine
tumours: a potential marker for malignancy
K Y Lam, C Y Lo, S T Fan, J M Luk
Abstract
Aims—Telomerase activation is known to
be a common event in human cancer and
may be a useful marker for malignancy. In
general, the histological features of pan-
creatic endocrine tumours cannot
be used to determine their malignant
potential. The aim of this study was to
investigate the role of testing telomerase
activity in pancreatic endocrine tumours.
Methods—Prospectively collected fresh
frozen tissue specimens from 10 patients
with pancreatic endocrine tumours (nine
insulinomas, one adrenocorticotrophin
producing pancreatic endocrine tumour)
were examined by a highly sensitive
polymerase chain reaction (PCR) based
telomerase repeat protocol (TRAP).
Results—Of the 10 pancreatic endocrine
tumours, three had telomerase activity.
The positive cases included two frankly
malignant tumours with liver metastases
and one pancreatic endocrine tumour
occurring in the setting of multiple
endocrine neoplasia type 1. The latter had
an infiltrative border. Vascular and
perineural tumour infiltration was noted.
In the twomalignant pancreatic endocrine
tumours with liver metastases, telomerase
activity was noted in the tumour and the
adjacent morphologically non-neoplastic
pancreas.
Conclusion—To our knowledge, this is the
first report of the role of telomerase activ-
ity in pancreatic endocrine tumours. Tel-
omerase activity might be useful for
distinguishing between benign and malig-
nant pancreatic endocrine tumours.
(J Clin Pathol:Mol Pathol 2000;53:133–136)
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Recently, telomere length and telomerase
activity have received much attention from the
biomedical research community.1 Human tel-
omeres (terminal chromosome regions) are
made up of several thousand copies of
repeating nucleotide sequences (TTAGGG)n.
Their main functions are believed to be the
stabilisation and protection of chromosomal
ends. These telomeric DNA sequences are not
fully replicated at each round of DNA synthe-
sis because of an “end replication problem” at
the 5' end of the daughter DNA. Progressive
shortening of these sequences is observed in
most somatic cells in the body except for the
germ line cells.
Telomerase is an important ribonucleopro-
tein that acts as an enzyme for the mainte-
nance of telomeres during cell division.2 It is
an RNA dependent DNA polymerase that
synthesises the telomeric DNA repeats by
using an RNA template (termed “hTR”)
subunit of the telomerase holoenzyme. The
enzyme is inactive in adult somatic cells,
except for germ cells, activated lymphocytes,
and stem cells of regenerative tissues. Raised
telomerase activity has been selectively dem-
onstrated in a large number of human
tumours.1 It has generated considerable ex-
citement for research workers and has been
proposed as a potential marker for malig-
nancy, a prognostic indicator, and a target of
future anticancer strategies.
Pancreatic endocrine tumours are an un-
common type of endocrine tumour. These
tumours present an important challenge to cli-
nicians because of their hormonal manifesta-
tions, associated morbidity, and potential
lethality.3 4 Unlike other tumours in general, it
is diYcult to assess the biological behaviour of
pancreatic endocrine tumours based on histo-
logical studies alone. The diagnosis of malig-
nancy usually depends on the presence of
metastases. Despite the recent boom in clinical
telomerase research, telomerase activity has
rarely been studied in pancreatic endocrine
tumours.5 In our study, we analysed the
presence of telomerase activity in pancreatic
endocrine tumours to evaluate the investiga-
tion of telomerase activity as a marker for pre-
dicting the biological behaviour of these
tumours. Possible correlations with clinico-
pathological parameters were also studied.
Patients and methods
COLLECTION OF TISSUES AND PATHOLOGICAL
EXAMINATION
The tissue samples were collected prospec-
tively from patients with pancreatic endocrine
tumours in the five year study period (1995 to
1999). The resection specimens were dissected
when fresh. Macroscopically, the site and size
(maximum dimension) of the pancreatic tu-
mours were recorded by one of us (KYL). In
each case, one representative frozen block from
the tumour and one from the non-neoplastic
pancreas were snap frozen in liquid nitrogen at
−70°C and stored until used. Other standard
blocks were then taken, fixed in 10% formalin,
and embedded in paraYn wax. Histological
sections (6 µm thick) of the paraYn wax and
frozen blocks were cut and stained with
haematoxylin and eosin for light microscopic
analysis. The diagnoses and clinicopathological
subtypes of the tumours were confirmed
with immunohistochemical stains using anti-
bodies, as in our previous study.6 The demo-
graphic data, clinical characteristics, laboratory
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findings, and follow up data were noted from
the clinical records. The preoperative localisa-
tion studies, biochemical investigations, hor-
monal studies, and postoperative follow up
(radiological, biochemical, and hormonal in-
vestigations) were standardised for each pa-
tient.
TELOMERASE ASSAYS
Frozen tissue specimens were sectioned on a
cryostat, and 10 × 10 µm thick sections from
each specimen were resuspended in 200 µl of
ice cold lysis buVer. After 30 minutes incuba-
tion on ice, the lysate was centrifuged at
16 000 ×g for 20 minutes at 4°C. The
supernatant was frozen in liquid nitrogen and
stored at −80°C. The protein concentration
of tissue extracts was determined by the
BioRad protein assay (Hercules, California,
USA).
Telomerase activity was assayed by the telo-
meric repeat amplification protocol (TRAP)
method as described by Kim et al.7 Two proto-
cols were used in our study: Telomerase
polymerase chain reaction (PCR) enzyme
linked immunosorbent assay (ELISA) (Boe-
hringer Mannheim, Indianapolis, USA) and
TRAP gel staining assay (Oncor,Gaithersburg,
Maryland, USA).
In PCR ELISA, 5 µl of tissue extracts (corre-
sponding to 3–5 µg total protein) was added to a
final volume of 50 µl of reaction mixture (0.1 µg
TS primer (5'-AATCCGTCGAGCAGAGTT-
3'), 0.1 µg CX primer (5'- CCCTTACCCTT
ACCCTTACCCTTA-3'), 50 µM dNTPs, and
2 U Taq polymerase in 20 mM Tris/HCl buVer
(pH 8.3)). A combined primer elongation/
amplification protocol was performed: (1)
primer elongation: 25°C for 30 minutes; (2) tel-
omerase inactivation: 94°C for five minutes; (3)
amplification (for 30 cycles): 94°C for 30
seconds (denaturation), 50°C for 30 seconds
(annealing), and 72°C for 90 seconds (polymeri-
sation), followed by a final extension step at
72°C for 10 minutes. After PCR, 5 µl of the
amplification product was treated with 20 µl of
denaturation solution for 10 minutes, and then
transferred to 225 µl of hybridisation buVer.
Duplicate 100 µl aliquots of the mixture were
then added to a microplate precoated with
streptavidin for capture of the biotinylated
amplicons. After hybridisation for two hours at
37°C, the plate was washed and horseradish
peroxidase conjugated antidigoxigenin Fab anti-
body was added. TMB substrate solution (con-
taining the peroxidase substrate, 3,3',5,5'-
tetramethyl benzidine) was used for colour
development, and optical absorbance at 450 and
690 nm was measured using an ELISA reader
(Molecular Devices, Sunnyvale, California,
USA). Heat inactivated tissue extracts (sub-
jected to 30 minutes treatment at 85°C before
the TRAP assay) were used as telomerase nega-
tive controls and extracts prepared from papil-
lary carcinoma of the thyroid (known to be posi-
tive for telomerase) were used as telomerase
positive controls.8 Each reading represented the
mean value of the A450 − 690 (sample) minus the
A450 − 690 (control). The criterion for a positive
telomerase assay was an A450 − 690 of 0.2 or
greater.
Alternatively, telomerase activity in tissue
extracts was determined by the Oncor telomer-
ase detection kit according to the manufactur-
er’s instructions. The TRAP reaction product
was analysed by electrophoresis in 0.5 M Tris/
borate EDTA buVer on 12% polyacrylamide
non-denaturing gels. The gels were soaked in
Syber Gold solution for visualisation. A typical
hexanucleotide ladder of three or more bands
was observed in the telomerase positive lane.
Results
Ten patients (six men, four women) with
pancreatic endocrine tumours were studied.
These comprised nine insulinomas and one
tumour with documented ectopic adrenocorti-
cotrophin (ACTH) production and carcinoid
syndrome. Table 1 shows the clinicopathologi-
cal characteristics and the results of the telom-
erase assay. The median age was 45 years
(range, 29 to 64). The median size of the pan-
creatic endocrine tumours was 1.5 cm (range,
1 to 7). There appeared to be no correlation
between tumour size and the results of the tel-
omerase assay. In all the tumours, no signifi-
cant lymphocytic infiltration was noted. Tel-
omerase activity results were similar for both
assays (PCR ELISA and TRAP silver staining
assay). Telomerase activity was positive in the
control tissue and three of 10 pancreatic endo-
crine tumours (fig 1).
Two patients presented with multiple liver
metastases. One of them (a 43 year old woman)
showed ectopic ACTH production and carci-
noid syndrome. This patient also developed
lung metastases and subsequently died of the
Table 1 Clinicopathological features and telomerase activity in pancreatic endocrine tumours (PETs)
Case/Race Sex/Age Site Tumour type Size (diameter) of PETs
Telomerase
activity
Optical
density Treatment
Follow up
(months) Remarks
1/Chinese M/46 Head Insulinoma 1.5 cm Negative – Enucleation 52, alive, NED
2/Chinese M/41 Multiple Insulinoma Multiple tumors, the
largest one: 6.0 cm at tail
Negative – Distal subtotal
pancreatectomy
46, alive NED Had MEN 1
3/Chinese F/43 Body Malignant ACTH
producing PET
1.0 cm Positive 1.9 Distal pancreotomy 18, died Metastases in
liver
4/Chinese M/22 Multiple Insulinoma Multiple tumours, the
largest one: 1.0 cm at tail
Positive 1.9 Distal subtotal
pancreatectomy
36, alive NED Had MEN 1
5/Indian F/49 Tail Insulinoma 1.5 cm Negative – Enucleation 16, alive, NED
6/Chinese M/29 Body Insulinoma 1.5 cm Negative – Distal pancreatectomy 21, alive NED
7/Chinese F/64 Tail Malignant insulinoma 7.0 cm Positive 1.4 Distal pancreatectomy 15, alive with
residual disease
Metastases in
liver
8/Chinese M/35 Tail Insulinoma 1.5 cm Negative – Distal pancreatectomy 11, alive NED
9/Chinese M/68 Head Insulinoma 1.0 cm Negative – Enucleation 4, alive, NED
10/Chinese F/65 Head Insulinoma 1.5 cm Negative – Enucleation 3, alive, NED
ACTH, adrenocorticotrophin; MEN 1, multiple endocrine neoplasia type 1; NED, no evidence of disease.
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disease 18 months after resection of the
pancreatic tumour. In both cases, telomerase
activity was documented in the pancreatic
tumour and the adjacent non-neoplastic pan-
creas.
Two of the nine insulinomas were found in
patients with multiple endocrine neoplasia type
1 (MEN 1). They showed multiple satellite
nodules. In one patient, the tumour showed an
infiltrative growth pattern. Vascular and
perineural tumour infiltration were present.
The resection margin was free of tumour. Bio-
logical behaviour was diYcult to predict,
because gross evidence of distant metastasis
was absent. Telomerase activity was positive in
this patient. In the other patient with MEN 1,
satellite nodules were seen in the peripancre-
atic soft tissue. No evidence of local infiltration
or distant metastasis was present. Telomerase
activity was negative in this patient. In the other
seven insulinomas, telomerase activity was
negative in tissue taken from the tumour and
adjacent non-neoplastic pancreas.
Discussion
Telomerase activity has been proposed to be
important in the proliferation of malignant
cells and to be correlated closely with the
malignant phenotype. More than 20 diVerent
tumour types have been tested for telomerase
activity, and approximately 85% of all tumours
have exhibited such activity.1 The only study
that analysed telomerase activity in human
pancreatic endocrine tumours was described
recently by Hiyama et al.5 They detected
telomerase activity in two of three pancreatic
tumours labelled “islet cell carcinomas” in a
study of telomerase activity in various types of
pancreatic cancer. The study provided no
information regarding the clinical presenta-
tions, pathological features of the tumours, or
follow up data of these patients.
In the present prospective study over a
period of three years, we prospectively col-
lected the tissues and analysed the telomerase
activity from our tumour tissue bank. Telomer-
ase activity was detected in three of the 10 pan-
creatic endocrine tumours. The telomerase
positive tumours comprised two malignant
pancreatic endocrine tumours with liver metas-
tases and one insulinoma occurring in the set-
ting of MEN 1. The telomerase positive
tumour in the patient with MEN 1 was infiltra-
tive and showed vascular and perineural
tumour permeation. In addition, two of the
three telomerase positive tumours were only
1 cm in diameter. Thus, telomerase was a
potential marker for malignancy in pancreatic
endocrine tumours and was positive even in
malignant pancreatic endocrine tumours of
small size.
A diVerent surgical strategy is needed for the
management of insulinomas in MEN 1.9 In our
study, both patients with MEN 1 had multiple
tumours in the pancreas. Telomerase activity
was seen in the insulinoma in one patient but
not in the other. Thus, telomerase activity did
not distinguish the patients with or without
MEN 1.
Telomerase activity has been demonstrated
in benign or tumour adjacent somatic tissue
samples.1 In some reports, telomerase activity
in tissues resulted from the presence of
activated lymphocytes.10 In our study, telomer-
ase activity was noted in the morphologically
non-neoplastic pancreas adjacent to the malig-
nant pancreatic endocrine tumours, whereas
no activity was detected in tissue next to benign
lesions. No intense lymphocyte infiltration was
present to account for the telomerase activity.
The reason for this finding is unknown. The
adjacent morphologically non-neoplastic tissue
in malignant pancreatic endocrine tumours
might be genetically unstable, or there might be
microinvasion that escapes detection (in rou-
tine microscopy) in the adjacent non-
neoplastic tissue to give rise to the presence of
telomerase activity. Nevertheless, the study of
telomerase activity in the non-tumorous tissue
adjacent to the tumour might also help predict
the malignant potential of pancreatic endo-
crine tumours.
Human cells in culture undergo a finite
number of divisions, during which the length of
telomeres declines and then the cells senesce.
This stage can be averted by mutations in the
tumour suppressor gene p53.1 Roos et al noted
that telomerase activity in breast cancer was
significantly associated with p53 over-
expression.11 In some other cancers, no such
relation was found.12 13 We have found no
evidence of p53 accumulation in a study
involving 52 pancreatic endocrine tumours
(including the cases noted in our present
study).14 Thus, no correlation was found
between p53 overexpression and telomerase
activity in pancreatic endocrine tumours. In
addition, alternative mechanisms have been
suggested for telomeric length stabilisation
other than telomerase activation.15
In summary, our study suggests that telom-
erase expression does play a role in distinguish-
ing between benign and malignant pancreatic
endocrine tumours. On the basis of this
preliminary study, documenting telomerase
Figure 1 Telomerase activation can be observed in both the positive control (thyroid
cancer) and one sample from a malignant endocrine tumour (P).N, normal tissue; T,
tumour tissue.
Markers Thyroid Pancreas
N T N T
Telomerase in pancreatic endocrine tumours 135
assay as a marker for biological aggressiveness
in pancreatic endocrine tumours should be
investigated.
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